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Introduction: Both micropapillary predominant lung adenocarci-
noma according to the IASLC/ATS/ERS classification and lung ade-
nocarcinoma with a micropapillary component have been reported 
to be associated with poor prognosis. However, whether they have 
different prognosis remains undetermined.
Methods: Out of 1302 lung adenocarcinoma patients, 21 patients 
with micropapillary predominant lung adenocarcinoma (MPP) 
and 100 patients with nonmicropapillary predominant tumors har-
boring a micropapillary component of at least 5% (MPC) were 
investigated for clinicopathologic characteristics, recurrence-free 
survival (RFS), overall survival (OS), and spectrum of well-identi-
fied driver mutations including EGFR, KRAS, HER2, BRAF, ALK, 
ROS1, and RET.
Results: Twenty out of 21 (95.2%) micropapillary predominant lung 
adenocarcinoma harbored driver mutations in EGFR (85.7%), HER2 
(4.8%), or RET (4.8%). MPP had significantly worse RFS than MPC in 
stage I patients (p = 0.003), but not in stages II–III patients. The over-
all survival was comparable between MPP and MPC regardless of dis-
ease stages. Objective response was achieved in 13 out of the 18 MPP 
or MPC patients with EGFR mutations who received EGFR tyrosine 
kinase inhibitors (TKIs) after disease recurrence. The postrecurrence 
survival was significantly better in EGFR-mutated patients who were 
treated with EGFR TKIs compared to those who did not receive TKIs 
(p = 0.003).
Conclusions: Micropapillary predominant lung adenocarcinoma is a 
disease that could be largely defined by targetable driver mutations. 
For stage I lung adenocarcinoma, MPP was even more likely to recur 
than MPC. EGFR TKIs might help to control the recurrent disease 
for MPP or MPC patients harboring EGFR mutations.
Key Words: Lung adenocarcinoma, Micropapillary pattern, Driver 
mutations, Prognosis.
(J Thorac Oncol. 2014;9: 1772–1778)
Lung cancer remains the leading cause of cancer-related deaths worldwide.1 Lung adenocarcinoma is the most common his-
tologic subtype which is increasing in prevalence.2 Molecularly, 
lung adenocarcinoma can be classified into oncogenic driver 
mutation-defined subsets, each with distinct clinicopathologic 
characteristics and potentials for targeted therapies.3 In 2011, 
a new lung adenocarcinoma classification system was pro-
posed by the International Association for the Study of Lung 
Cancer (IASLC)/American Thoracic Society (ATS)/European 
Respiratory Society (ERS).4 Histologic subtypes of lung adeno-
carcinoma according to this classification correlate significantly 
with oncogenic driver mutations and patient prognosis.5–10
Micropapillary pattern is characterized by tumor cells 
growing in papillary tufts, which lack fibrovascular cores.4 Lung 
adenocarcinoma with a micropapillary pattern was reported 
to be associated with lymph node metastasis.11,12 In stage I 
lung adenocarcinomas, micropapillary predominant adeno-
carcinomas had significantly worse disease-free survival.9,13 
Micropapillary component of 5% or greater was found to be 
associated with increased risk of recurrence after limited resec-
tion for small sized lung adenocarcinomas.14 However, there 
remains controversy over the prognostic value of micropapillary 
pattern in patients with advanced lung adenocarcinomas.10,15–17
Although the IASLC/ATS/ERS classification system rec-
ommends the addition of “micropapillary predominant adenocar-
cinoma” as a major histologic subtype when applicable as well 
as the assessment of histologic patterns semiquantitatively in 5% 
increments, it is still undetermined whether nonmicropapillary 
predominant lung adenocarcinoma with a micropapillary pattern 
of greater than or equal to 5% have different prognosis compared 
to micropapillary predominant adenocarcinoma. Therefore, we 
undertook a comprehensive investigation of the clinicopatho-
logic characteristics and oncogenic mutational spectrum of lung 
adenocarcinoma harboring a micropapillary component of at 
least 5%, with specific focus on the comparison between nonmi-
cropapillary predominant adenocarcinoma with a micropapillary 
pattern and micropapillary predominant tumors.
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MATERIALS AND METHODS
From October 2007 to May 2013, we consecutively col-
lected lung tumors resected at the Department of Thoracic 
Surgery, Fudan University Shanghai Cancer Center, Shanghai, 
China. Inclusion criteria for this study included: (1) the patients 
underwent complete resection with curative intent; (2) patho-
logically confirmed lung adenocarcinoma with a minimum of 
50% of tumor cells and sufficient tissue for comprehensive 
mutational analyses. Patients were excluded from this study if 
they received neoadjuvant chemotherapy or radiotherapy.
Pathologic slides were re-reviewed by two certified 
pathologists (Lei Shen and Yuan Li) to classify histologic sub-
types of lung adenocarcinoma according to the IASLC/ATS/
ERS multidisciplinary classification system.4 The abbrevia-
tion “MPP” was used to represent micropapillary predominant 
lung adenocarcinoma. The abbreviation “MPC” was used to 
define lung adenocarcinoma with a micropapillary component 
of at least 5%, but micropapillary was not the predominant 
pattern. Lung adenocarcinoma with a micropapillary pattern 
of less than 5% was defined as “MPC-negative”. The follow-
ing clinicopathologic parameters were also collected: gender, 
age at diagnosis, smoking history, type of surgical resection, 
tumor location, lymphovascular invasion, and pathologic TNM 
stage in line with the seventh edition of the lung cancer staging 
system.18 Recurrence-free survival (RFS) and overall survival 
(OS) were recorded based on follow-up clinic or telephone. 
This study was approved by our institutional review board. 
Written informed consent was obtained from all patients.
Mutational Analysis
After frozen tumor specimens were dissected into Trizol 
(Invitrogen, Carlsbad, CA), RNA was extracted as per standard 
protocol and was reverse transcribed into cDNA. EGFR (exons 
18–22), HER2 (exons 18–21), KRAS (exons 2–3), and BRAF 
(exons 11–15) were amplified by PCR using cDNA. Direct 
dideoxynucleotide sequencing was then performed to analyze 
the amplified products. A combination strategy of quantita-
tive real-time PCR (qRT-PCR) and reverse transcriptase PCR 
(RT-PCR) was used to detect ALK, ROS1, and RET fusions, 
with validation using fluorescent in situ hybridization (FISH).19
Statistical Analysis
Pearson’s χ2 test or Fisher’s exact test was used to inves-
tigate the correlations between two categorical variables. The 
association between one categorical variable and one continuous 
variable was assessed using independent sample t test. The 
RFS and OS distribution was analyzed using the Kaplan–Meier 
method, and log-rank tests were employed for comparisons 
of RFS or OS between two categories in univariate analysis. 
Multivariate survival analysis was conducted using the Cox pro-
portional hazards regression (forward likelihood ratio model) to 
identify independent prognostic factors. Statistical analysis was 
performed in SPSS 16.0 (SPSS Inc, Chicago, IL). All tests were 
two tailed. Statistical significance was set at p < 0.05.
RESULTS
Clinicopathologic Factors
One hundred twenty-one lung adenocarcinoma harbor-
ing a micropapillary component of at least 5% were identi-
fied out of a total of 1302 lung adenocarcinoma, of which 
21 were micropapillary predominant lung adenocarcinoma 
(MPP), the remaining 100 nonmicropapillary predominant 
lung adenocarcinoma with a micropapillary component were 
defined as “MPC”. Representative images of MPP and MPC 
are shown in Fig. 1. There were 68 (56.2%) women and 53 
(43.8%) men, ranging in age from 37 to 80 years (median, 62 
years). The number of patients in stages I, II, and III was 46, 
22, and 53, respectively. Lymphovascular invasion was found 
in 33 (27.3%) samples (Tables 1, 12).
Compared to lung adenocarcinoma with a micropapil-
lary component of less than 5% (MPC-negative), MPP and 
MPC (MPC-positive) patients had significantly older age at 
diagnosis (p = 0.020), larger tumor size (p = 0.015), higher 
prevalence of lymphovascular invasion (p < 0.001), and lymph 
node metastasis (p < 0.001), and more advanced disease stage 
(p < 0.001).
We further compared the clinicopathologic features 
between MPP and MPC. Demographic characteristics includ-
ing gender and age were not significantly different between the 
two categories, neither was the smoking history. The extent of 
micropapillary pattern was not significantly correlated with 
tumor size, lymph node metastasis, pathologic stage, and lym-
phovascular invasion (Table 2).
Status of Common Driver Mutations
There were ninety-three (76.9%) EGFR mutations, 
three (2.5%) KRAS mutations, two (1.7%) HER2 mutations, 
one(0.8%) BRAF mutations, four (3.3%) ALK fusions, and two 
(1.7%) RET fusions in the 121 MPC-positive patients (Table 2, 
FIGURE 1.  Representative images 
of micropapillary predominant lung 
adenocarcinoma (A) and nonmicro-
papillary predominant (acinar pre-
dominant) adenocarcinoma with a 
micropapillary component of greater 
than or equal to 5% (B).
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Fig. 2). All were mutually exclusive. No ROS1 fusions were 
detected. Twenty out of the 21 (95.2%) micropapillary predom-
inant lung adenocarcinomas harbored a known driver mutation 
in just three genes: EGFR (85.7%), HER2 (4.8%), and RET 
(4.8%). The frequency of common driver mutations did not 
significantly vary with the extent of micropapillary component.
Survival Analysis
Survival outcomes were compared between 121 MPC-
positive patients and 272 consecutive MPC-negative patients 
diagnosed from October 2007 to March 2010 (because of 
relatively sufficient follow-up duration). The median follow-
up duration of these patients were 35 months (range: 1–78 
months). Sixty MPC-positive patients (12 MPP and 48 MPC) 
and 142 MPC-negative patients had recurrent disease. Twenty-
eight MPC-positive patients (5 MPP and 23 MPC) and 68 
MPC-negative patients died during follow-up. MPC-positive 
lung adenocarcinoma patients had significantly worse RFS (p 
= 0.016) and OS (p = 0.025) than the MPC-negative counter-
parts (Fig. 3A, B). However, when the survival analysis was 
limited to stage I (Fig. 3C, D) or stages II–III (Fig. 3E, F) 
patients, RFS or OS was not significantly different between 
MPC-positive and MPC-negative patients. Compared to MPC-
negative patients, MPC (not including MPP) patients had 
significantly worse RFS in the entire cohort (p = 0.044, Fig. 
3A) as well as in the stages II–III group (p = 0.023, Fig. 3E), 
and significantly worse OS in all patients (p = 0.036, Fig. 3B). 
MPP patients had significantly worse RFS than MPC-negative 
patients in the stage I patient group (p < 0.001, Fig. 3C).
We then focused on the survival analysis of the 121 
MPC-positive patients. In univariate analysis, micropapillary 
predominant lung adenocarcinoma (MPP) and nonmicropapil-
lary predominant lung adenocarcinoma with a micropapillary 
component of at least 5% (MPC) had comparable recurrence-
free survival (p = 0.457, Fig. 3A) and OS (p = 0.888, Fig. 3B). 
TABLE 1.  Clinicopathologic Characteristics of Lung 
Adenocarcinoma According to Micropapillary Component
Variables
MPC-Positive  
(n = 121)
MPC-Negative  
(n = 1181) p
Gender 0.891
  Female 68 (56.2%) 656 (55.5%)
  Male 53 (43.8%) 525 (44.5%)
Age (y) 0.020
  Mean 61.6 59.3
  SD 9.9 10.2
Smoking history 0.613
  Ever 35 (28.9%) 368 (31.2%)
  Never 86 (71.1%) 813 (68.8%)
Tumor size (cm) 0.015
  >3.0 41 (33.9%) 282 (23.9%)
  ≤3.0 80 (66.1%) 899 (76.1%)
N status < 0.001
  N0 54 (44.6%) 818 (69.3%)
  N1/N2 67 (55.4%) 363 (30.7%)
Stage < 0.001
  I 46 (38.0%) 748 (63.3%)
  II–III 75 (62.0%) 433 (36.7%)
Lymphovascular 
invasion
< 0.001
  Present 33 (27.3%) 144 (12.2%)
  Absent 88 (72.7%) 1037 (87.8%)
MPC-positive, lung adenocarcinoma with a micropapillary component of greater 
than or equal to 5%; MPC-negative, lung adenocarcinoma with a micropapillary 
component of less than 5%; SD, standard deviation.
TABLE 2.  Clinicopathologic and Molecular Features of 
Micropapillary Predominant Lung Adenocarcinoma (MPP) and 
Nonmicropapillary Histologic Subtypes with a Micropapillary 
Component of greater than or equal to 5% (MPC)
Variable
MPP  
(n = 21)
MPC  
(n = 100) p
Gender 0.175
  Female 9 (42.9%) 59 (59%)
  Male 12 (57.1%) 41 (41%)
Age (y) 0.214
  >62 13 (61.9%) 47 (47%)
  ≤62 8 (38.1%) 53 (53%)
Smoking history 0.969
  Ever 6 (28.6%) 29 (29%)
  Never 15 (71.4%) 71 (71%)
Location 0.374
  Central 0 6 (6%)
  Peripheral 21 (100%) 94 (94%)
Extent of surgery 1.000
  Lobectomy 21 (100%) 97 (97%)
  Bi-lobectomy 0 2 (2%)
  Pneumonectomy 0 1 (1%)
Tumor size (cm) 0.516
  >3.0 6 (28.6%) 36 (36%)
  ≤3.0 15 (71.4%) 64 (64%)
N status 0.508
  N0 8 (38.1%) 46 (46%)
  N1/N2 13 (61.9%) 54 (54%)
Stage 0.627
  I 7 (33.3%) 39 (39%)
  II–III 14 (66.7%) 61 (61%)
Lymphovascular 
invasion
0.142
  Present 3 (14.3%) 30 (30%)
  Absent 18 (85.7%) 70 (70%)
Mutational status
  EGFR mutation 18 (85.7%) 75 (75%) 0.398
  KRAS mutation 0 3 (3%) 1.000
  HER2 mutation 1 (4.8%) 1 (1%) 0.318
  BRAF mutation 0 1 (1%) 1.000
  ALK fusion 0 4 (4%) 1.000
  RET fusion 1 (4.8%) 1 (1%) 0.318
MPP, micropapillary predominant lung adenocarcinoma; MPC, non-micropapillary 
predominant lung adenocarcinoma with a micropapillary component of greater than or 
equal to 5%.
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Older age at diagnosis (>62 years versus ≤62 years, p = 0.026), 
lymphovascular invasion (p = 0.031), N status (N0 vs. N1/N2, 
p < 0.001), and pathologic stage (stage I versus stage II/III, 
p < 0.001) were significantly associated with RFS. Older age at 
diagnosis (>62 years versus ≤62 years, p = 0.046), lymphovascu-
lar invasion (p = 0.043), lymph node metastasis (p = 0.002), and 
more advanced disease stage (p = 0.002) were significantly cor-
related with worse OS (Supplementary Table S1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A690). When the 
survival analysis was limited to stage I patients, MPP had sig-
nificantly worse RFS than MPC (p < 0.001, Fig. 3C), although 
the OS was not significantly different (p = 0.479, Fig. 3D). In 
stages II–III patients, the RFS (p = 0.214, Fig. 3E) and OS 
(p = 0.762, Fig. 3F) did not differ significantly between MPP 
and MPC. None of the stage IA patients received adjuvant 
chemotherapy. In the 75 stages II–III patients, seven patients 
did not receive adjuvant chemotherapy because of elder age or 
other factors which made chemotherapy intolerable. Stages II–
III patients who received postoperative adjuvant chemotherapy 
had comparable RFS (p = 0.938) and OS (p = 0.608) than those 
who did not. In multivariate analysis incorporating sex, age, 
smoking history, tumor location, T status, N status, pathologic 
stage (stage II/III versus stage I), lymphovascular invasion and 
mutational status, pathologic stage was the only independent 
predictor of RFS (odds ratio = 4.215, 95% confidence interval: 
2.165–8.208, p < 0.001) and OS (odds ratio = 4.527, 95% con-
fidence interval: 1.567–13.079, p = 0.005).
Of the 100 MPC, the predominant histologic subtype 
was acinar in sixty-four patients, papillary in twenty-six 
patients, solid in five patients, lepidic in three patients, and 
invasive mucinous adenocarcinoma in two patients. Survival 
curves of RFS and OS of MPP, acinar predominant adenocar-
cinoma, papillary predominant adenocarcinoma, and solid pre-
dominant adenocarcinoma (the number of lepidic predominant 
adenocarcinoma and invasive mucinous adenocarcinoma was 
too small) are shown in Supplementary Fig. S1 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A691). There was 
no statistically significant difference regarding RFS or OS 
when comparing one histologic subtype to another.
We further examined the effect of EGFR tyrosine kinase 
inhibitors (TKIs) on the postrecurrence survival of MPC-
positive patients harboring EGFR mutations (Fig. 4). A total 
of 46 patients with EGFR mutations experienced recurrence 
during follow-up, of which 18 received EGFR TKIs (gefitinib 
or erlotinib) after recurrence (Supplementary Table S2, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A692). Objective response was achieved in 13 out of the 18 
patients (1 complete response and 12 partial response), and 
the remaining five patients had stable disease at the first evalu-
ation. The postrecurrence survival was significantly better in 
patients who were treated with EGFR TKIs compared to those 
who did not receive TKIs (p = 0.003).
DISCUSSION
The new IASLC/ATS/ERS classification system rec-
ommends the assessment of histologic patterns semiquantita-
tively in 5% increments,4 it is therefore necessary to elucidate 
whether the prognosis is different between micropapillary pre-
dominant lung adenocarcinoma and nonmicropapillary pre-
dominant adenocarcinoma with a micropapillary component 
of at least 5%, since if prognosis is comparable between the 
two groups, just reporting a micropapillary pattern if present 
will be sufficient enough, and the classification of “micropap-
illary predominant lung adenocarcinoma” might be deleted.
Previous studies have investigated the prognostic value 
of lung adenocarcinoma with a micropapillary pattern in com-
parison to those without such pattern, or micropapillary pre-
dominant lung adenocarcinoma compared to other histologic 
subtypes.7,9,10,13–15,17,20–25 In this study, we also found that RFS 
and OS were significantly worse in MPC-positive patients than 
their MPC-negative counterparts. However, as far as we were 
concerned, this study represents the first comparison study 
between micropapillary predominant adenocarcinoma and 
nonmicropapillary predominant adenocarcinoma with a micro-
papillary component of at least 5% with regards to clinicopath-
ologic characteristics, mutational spectrum, and prognosis.
De Oliveira Duarte Achcar et al.26 investigated muta-
tional status of EGFR, KRAS, and BRAF in 15 lung adeno-
carcinomas with a micropapillary growth pattern of at least 
75% from a western population, and found 11 (73%) harbored 
mutually exclusive mutations in one of the three genes. A 
study of 440 Japanese lung adenocarcinoma patients revealed 
that EGFR mutations were present in 40.1% of the MPP sub-
type.7 Here, we observed the majority (20 out of 21, 95.2%) 
of micropapillary predominant lung adenocarcinoma from a 
Chinese cohort harbored driver mutations in EGFR (85.7%), 
HER2 (4.8%), or RET (4.8%). It should be noted that these 
FIGURE 2.  Spectrum of oncogenic 
driver mutations in micropapillary 
predominant lung adenocarcinoma 
(MPP) and nonmicropapillary pre-
dominant adenocarcinoma with a 
micropapillary component of greater 
than or equal to 5% (MPC).
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mutation types all can be targeted by TKIs. Given the aggres-
sive nature of lung adenocarcinomas with a micropapil-
lary pattern and the potential efficacy of TKIs, our findings 
have implications for clinical therapeutic strategies targeting 
micropapillary predominant lung adenocarcinoma.
Lung adenocarcinoma manifested a micropapillary pat-
tern that was reported to be associated with lymphovascular 
invasion, lymph node involvement, and more advanced disease 
stage.11,12,22 In this study, a higher prevalence of lymphovascu-
lar invasion, lymph node metastasis and more advanced disease 
stage was also observed in lung adenocarcinoma with a micro-
papillary component of greater than or equal to 5% compared 
to those harboring a micropapillary pattern of less than 5%. 
However, we found no significant difference regarding TNM 
stage and lymphovascular invasion between micropapillary 
predominant lung adenocarcinoma and nonmicropapillary pre-
dominant adenocarcinoma with a micropapillary component 
of greater than or equal to 5%. This suggested that a small pro-
portion of micropapillary pattern might be sufficient enough 
to cause lymphovascular invasion and lymph node metastasis.
Previous studies have demonstrated that both micropap-
illary predominant subtype and micropapillary component of 
5% or greater were associated with an increased risk of recur-
rence in stage I lung adenocarcinoma.9,13,14 We further found 
that in stage I patients, micropapillary predominant lung 
adenocarcinoma had significantly worse RFS than nonmicro-
papillary predominant adenocarcinoma with a micropapil-
lary pattern of at least 5%. However, OS was not significantly 
FIGURE 3.  Recurrence-free survival and overall survival of micropapillary predominant lung adenocarcinoma (MPP), nonmicro-
papillary histologic subtype with a micropapillary component of greater than or equal to 5% (MPC) and MPC-negative adeno-
carcinoma in patients of all stages (A and B), stage I (C and D), and stages II–III (E and F). “MPC-” represents MPC-negative. 
“MPC+” represents MPC-positive, including MPP and MPC.
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different between the two groups. This could be in part due 
to the relatively small number of cases and short follow-up. 
Another explanation might be micropapillary predominant 
adenocarcinomas respond well to platinum-based chemother-
apy15 and EGFR TKIs.21 Campos-Parra et al. 15 investigated 
the relevance of the IASLC/ATS/ERS classification in lung 
adenocarcinoma in advanced disease stage, and found a bet-
ter OS of micropapillary predominant lung adenocarcinoma 
owing to a better response to chemotherapy. This could explain 
our observations that in stages II–III lung adenocarcinomas, 
micropapillary predominant subtype, and nonmicropapillary 
subtype with a micropapillary component had comparable 
RFS and OS, since postoperative adjuvant chemotherapy was 
recommended for these patients Accordingly, the extremely 
worse RFS of stage I MPP patients and the relatively better 
RFS of stages II–III MPP patient might be due to the fact that 
only one of the seven stage I MPP patients (this patient was 
staged as IB) received adjuvant chemotherapy, whereas all the 
stages II–III MPP patients were treated with adjuvant chemo-
therapy. Our findings suggested that postoperative chemother-
apy might be considered for stage I MPP patients.
Sumiyoshi et al.21 reported that lung adenocarcinomas 
with micropapillary component could be well controlled with 
EGFR TKIs after recurrence. Consistent with their results, we 
found that for MPC-positive patients harboring EGFR muta-
tions, the postrecurrence survival was significantly better in 
patients who received gefitinib or erlotinib compared to those 
who did not. A high response rate (13 out of 18, 72.2%) was 
observed in these patients treated with TKIs. We therefore 
recommend the active application of EGFR TKIs for MPC-
positive patients harboring EGFR mutations who experienced 
disease recurrence.
There are several limitations of this study. First, the fol-
low-up duration for estimating RFS and OS may not be long 
enough as these tumors were resected between 2007 and 2013. 
Second, the finding that MPP had significantly worse RFS 
than MPC in stage I patients was based on a small number of 
patients (n = 7 for MPP). It should be validated in larger series 
of patients. Finally, although we recommended EGFR TKIs 
for EGFR-mutated patients who had recurrent disease, the 
administration of EGFR TKIs was largely based on patients’ 
own preferences as well as their economic status since the 
expense of EGFR TKIs (gefitinib and erlotinib) is not covered 
by insurance in China. This could be a potential bias.
In conclusion, micropapillary predominant lung adeno-
carcinoma is a disease that could be largely defined by targe-
table driver mutations. For stage I lung adenocarcinoma, MPP 
was even more likely to recur than MPC and should be distin-
guished from MPC. However, the survival of MPP and MPC 
might not differ in stages II–III patients. EGFR TKIs might 
help to control the recurrent disease for MPC-positive patients 
with EGFR mutations.
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